Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155616 | 0.98 | ALOX5 (0.39) | CYSLTR2CYSLTR1KMT2AMEN1BCHE | |
| SCHEMBL6155510 | 0.97 | MAPK1 (0.39) | CYSLTR2CYSLTR1KMT2AMEN1BCHE | |
| SCHEMBL5968372 | 0.91 | PTGER3 (0.41) | CYSLTR2CYSLTR1KMT2AMEN1BCHE | |
| SCHEMBL2106608 | 0.89 | MRGPRX4 (0.42) | ALOX5SMN1; SMN2TP53NFKB1FFAR1 | |
| SCHEMBL6155587 | 0.89 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1KMT2AMEN1BCHE | |
| SCHEMBL6155468 | 0.87 | NPC1 (0.42) | KMT2AMEN1BCHEALOX5TSHR | |
| SCHEMBL6155248 | 0.86 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1KMT2AMEN1BCHE | |
| SCHEMBL2785501 | 0.84 | VDR (0.49) | CYSLTR2CYSLTR1BCHEALOX5FFAR1 | |
| SCHEMBL6155609 | 0.82 | VDR (0.48) | CYSLTR2CYSLTR1BCHEALOX5FFAR1 | |
| SCHEMBL6154639 | 0.82 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1KMT2AALOX5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | claimed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | claimed |
| CN-1282636-C | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2006-11-01 | — | — | CN | claimed |
| EP-1686972-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | Galderma Research & Development, S.N.C. (FR) | 2006-08-09 | — | — | EP | claimed |
| WO-2005053666-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | WO | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| EP-2251004-A2 | Pharmaceutical or cosmetic composition and a mixed solubilisation method for the production thereof | Galderma Research & Development (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1951199-A2 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND A MIXED SOLUBILISATION METHOD FOR THE PRODUCTION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-08-06 | — | — | EP | disclosed |
| EP-1952808-A2 | Composition in the form of a spray comprising calcitriol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-08-06 | — | — | EP | disclosed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | disclosed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | CYP24A1, CYP2R1, VDR | CYSLTR2 509/4885CYSLTR1 368/4885KMT2A 4836/4885 |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | CYP19A1, CYP17A1, CYP51A1 | CYSLTR2 462/4885CYSLTR1 295/4885KMT2A 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.